Citations

Clear

696 citation(s) found for "Tyler, A".

Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease
Haley, Connie A. , Ashkin, David , Peloquin, Charles A. , Cegielski, J. Peter , Andrino, Barbara B, Burgos, Marcos, Caloia, Lori A, Chen, Lisa , Colón‐Semidey, Angel, DeSilva, Malini B. , Dhanireddy, Shireesha , Dorman, Susan E. , Dworkin, Felicia , Hammond-Epstein, Heidi, Easton, Alice V. , Gaensbauer, James , Ghassemieh, Bijan J., Gómez, María Elena, Horné, David , Jasuja, Supriya , Jones, Betsy A., Kaplan, Leonard J., Khan, Asharaf Edward, Kracen, Elizabeth, Labuda, Sarah M. , Landers, Karen M., Lardizabal, Alfred , Lasley, Maria T, Letzer, David, Lopes, Vinicius K, Lubelchek, Ronald , Macias, C. Patricia, Mihalyov, Aimee, Misch, Elizabeth Ann , Murray, Jason A., Nilsen, Diana , Ninneman, M.J., Ogawa, Lynne, Oladele, Alawode, Overman, Melissa C, Ritger, Kathleen A., Rowlinson, Marie‐Claire , Sabuwala, Nadya, Schiller, Thomas M, Schwartz, Lawrence E., Spitters, Christopher, Thomson, Douglas B, Tresgallo, Rene Rico, Valois, Patrick , Goswami, Neela D. , Group, for the BPaL Implementation, Agraz-Lara, Rocio, Ahmed, Amina , Alvarez, Ana , Armitage, Lisa, Belknap, Robert , Bravo, Mary, Brode, Sarah K. , Burden, Elizabeth, Burzynski, Joseph , Caplan‐Shaw, Caralee , Castro, Ken, Chorba, Terry, Cook, Victoria , Cruz, Andrea T. , Dasgupta, Shom, Dhingra, Sonia, Elmore, Ellen, Erwin, Frank, Escuyer, Vincent, Fiske, Christina T. , Gadkowski, Beth, Henestroza, Germán, Higashi, Julie, Keh, Chris , Khalil, Amanda , Kigonya, Lilian, Lauzardo, Michael , Morris, Sapna Bamrah , Nabity, Scott A. , Oxtoby, Margaret J., Patrawalla, Amee , Raftery, Ann, Reed, Caitlin , Rock, Brian, Russo, Kelly, Sahini, Harleen, Saleeb, Paul , Santos, Roberto P. , Seaworth, Barbara , Shaw-Kaikai, Joanna, Starke, J R, Stout, Jason E. , Stubblefield, Wesley, Temesgen, Zelalem , Thomas, Keziah, Urbine, Daniel , Warkentin, Jon, Webb, Risa M. , Wortham, Johnathan, Yu, and Salinia, Altman, C, Hafiz, Irfan, Prabhakar, Deepa, Bowler, William, Gaensbauer, James T , Peloquin, Charles A , Schechter, Marcos C , Narita, Masahiro , Ray, Susan M , Group, for the BPaL Implementation, Alvarez, Ana, Armitage, Lisa, Barry, Pennan M. , Bernardo, John , Connors, William J. A. , Daley, Charles L. , Dobbs, Thomas E. , Escuyer, Vincent , Katrak, Shereen S. , Munsiff, Sonal S. , Phillips, Allison, Stubblefield, Wes, Thomas, Keziah, Tornheim, Jeffrey A. , Upton, Caryn M. , Wang, Shuhua , Wilson, John , Altman, Claudia

Mayo Clinic

Clinical Infectious Diseases | May 30, 2023 | Volume: 77 | Issue: 7 | Pages: 1053-1062

10.1093/cid/ciad312 | PMID 37249079 Get It

Abstract Background Rifampin-resistant tuberculosis is a leading cause of morbidity worldwide; only one-third of persons start treatment, and outcomes are often inadequate. Several trials demonstrate 90% efficacy using an all-oral, 6-month regimen of bedaquiline, pretomanid, and linezolid (BPaL), but significant toxicity occurred using 1200-mg linezolid. After US Food and Drug Administration approval in 2019, some US clinicians rapidly implemented BPaL using an initial 600-mg linezolid dose adjusted by serum drug concentrations and clinical monitoring. Methods Data from US patients treated with BPaL between 14 October 2019 and 30 April 2022 were compiled and analyzed by the BPaL Implementation Group (BIG), including baseline examination and laboratory, electrocardiographic, and clinical monitoring throughout treatment and follow-up. Linezolid dosing and clinical management was provider driven, and most patients had linezolid adjusted by therapeutic drug monitoring. Results Of 70 patients starting BPaL, 2 changed to rifampin-based therapy, 68 (97.1%) completed BPaL, and 2 of the 68 (2.9%) experienced relapse after completion. Using an initial 600-mg linezolid dose daily adjusted by therapeutic drug monitoring and careful clinical and laboratory monitoring for adverse effects, supportive care, and expert consultation throughout BPaL treatment, 3 patients (4.4%) with hematologic toxicity and 4 (5.9%) with neurotoxicity required a change in linezolid dose or frequency. The median BPaL duration was 6 months. Conclusions BPaL has transformed treatment for rifampin-resistant or intolerant tuberculosis. In this cohort, effective treatment required less than half the duration recommended in 2019 US guidelines for drug-resistant tuberculosis. Use of individualized linezolid dosing and monitoring likely enhanced safety and treatment completion. The BIG cohort demonstrates that early implementation of new tuberculosis treatments in the United States is feasible.
(262) Grumpy Young Men? Factors Associated with Bother in Men with Peyronie’s Disease
Tyler, A, Green, B, Brearton, K, Ziegelmann, M., Helo, S, Kohler, T, Trost, Landon , Savage, Joshua S. , Helo, S

Mayo Clinic

The Journal of Sexual Medicine | May 22, 2023 | Volume: 20 | Issue: Supplement_1 | Pages: No page available

10.1093/jsxmed/qdad060.247 Get It

Abstract Introduction Age is often correlated with various medical conditions, including bother with the condition itself. Peyronie’s disease (PD) is a condition which is most often associated with men in their 50-60’s, however, it does affect younger men as well. Anecdotally, younger men with PD appear to be more bothered by their condition compared to older men. We therefore sought to evaluate whether there is a difference among older vs younger men as to the degree of bother linked to PD. Objective To evaluate age as a potential predictor of bother associated with PD. Methods A prospective database has been maintained of men seeking treatment for PD. Beginning in Feb 2020, we began implementing men routinely completed standardized intake questionnaires relating to PD, including the Peyronie’s Disease Questionnaire (PDQ). The PDQ consists of 15 questions broken down into three key subdomains: psychological and physical, penile pain, and symptom bother. Men who had completed the PDQ questionnaire were evaluated to determine the correlation between various clinicopathologic variables and the PDQ-bother domain. Results A total of 645 men were seen for symptoms of PD and had PDQ questionnaire data available for review. Baseline demographics included a mean age was 51.8 years (SD 17.6), mean PD symptom duration 31.3 months (SD 65.3), estimated curve of 40.9 degrees (SD 26.8), and mean PDQ-Bother score 8.9 (SD 3.1 – Note: lower is better). Several clinicopathology variables were found to be associated with increased PDQ-bother scores, including age (younger = less bothered, parameter estimate -.0.03, p=0.03), the presence of indentation or hourglass (yes 9.4, no 8.4, p<0.05), pain (yes 9.3, no 8.5, p=0.16), PD preventing penetrative intercourse (yes 9.5, no 8.7, p=0.07), penile shortening (yes 9.3, no 8.7, p=0.10), subjective erectile dysfunction (yes 9.6, no 8.5, p<0.01), and subjective premature ejaculation (yes 9.8, no 8.4, p<0.01). Interestingly, several variables did not correlate, including the duration of relationship, frequency of intercourse, duration of symptoms, direction of curve, degree of curvature, partner pain with intercourse, or libido. Conclusions Several notable factors are associated with PD bother (as assessed by the PDQ-bother domain), and equally importantly, several factors are surprisingly not associated (e.g. curvature degree and direction). These factors provide useful information to the practicing clinician to help better identify men who may be at greater risk for bother associated with the condition. Disclosure No
Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Wang, Qiao-Li , Ma, Chao , Yuan, Chen , Shi, Qian , Wolpin, Brian M. , Zhang, Yin , Fuchs, Charles S. , Meyer, Jeffrey , Zemla, Tyler , Cheng, En , Kumthekar, Priya , Guthrie, Katherine A. , Couture, Félix , Kuebler, Philip , Kumar, Pankaj , Tan, Benjamin , Krishnamurthi, Smitha , Goldberg, Richard M. , Blanke, Charles D. , Shields, Anthony F. , Meyerhardt, Jeffrey A. , Ng, Kimmie , Kuebler, J. Philip , Venook, Alan P , Shields, Anthony F , O'Reilly, Eileen M , Meyerhardt, Jeffrey A , Ng, Kimmie , Shi, Qian , Zemla, Tyler J , Yuan, Chen , Venook, Alan P. , O’Reilly, Eileen M. , Cheng, En

Mayo Clinic

Clinical Cancer Research | May 11, 2023 | Volume: 29 | Issue: 14 | Pages: 2621-2630

10.1158/1078-0432.ccr-23-0447 | PMID 37289007 Get It

Abstract Purpose: To assess whether higher plasma 25-hydroxyvitamin D [25(OH)D] is associated with improved outcomes in colon cancer and whether circulating inflammatory cytokines mediate such association. Experimental Design: Plasma samples were collected from 1,437 patients with stage III colon cancer enrolled in a phase III randomized clinical trial (CALGB/SWOG 80702) from 2010 to 2015, who were followed until 2020. Cox regressions were used to examine associations between plasma 25(OH)D and disease-free survival (DFS), overall survival (OS), and time to recurrence (TTR). Mediation analysis was performed for circulating inflammatory biomarkers of C-reactive protein (CRP), IL6, and soluble TNF receptor 2 (sTNF-R2). Results: Vitamin D deficiency [25(OH)D <12 ng/mL] was present in 13% of total patients at baseline and in 32% of Black patients. Compared with deficiency, nondeficient vitamin D status (≥12 ng/mL) was significantly associated with improved DFS, OS, and TTR (all Plog-rank<0.05), with multivariable-adjusted HRs of 0.68 (95% confidence interval, 0.51–0.92) for DFS, 0.57 (0.40–0.80) for OS, and 0.71 (0.52–0.98) for TTR. A U-shaped dose–response pattern was observed for DFS and OS (both Pnonlinearity<0.05). The proportion of the association with survival that was mediated by sTNF-R2 was 10.6% (Pmediation = 0.04) for DFS and 11.8% (Pmediation = 0.05) for OS, whereas CRP and IL6 were not shown to be mediators. Plasma 25(OH)D was not associated with the occurrence of ≥ grade 2 adverse events. Conclusions: Nondeficient vitamin D is associated with improved outcomes in patients with stage III colon cancer, largely independent of circulation inflammations. A randomized trial is warranted to elucidate whether adjuvant vitamin D supplementation improves patient outcomes.
Comparison of first-line radiosurgery for small-cell and non-small cell lung cancer brain metastases (CROSS-FIRE)
Rusthoven, Chad G. , Staley, Alyse , Yomo, Shoji , Bernhardt, Denise , Wandrey, Narine , Shafie, Rami A. El , Kraemer, Anna, Padilla, Oscar , Chiang, Veronica , Faramand, Andrew , Wegner, Rodney E. , Hattangadi‐Gluth, Jona A. , Lévy, Antonin , Bernstein, Kenneth , Mathieu, David , Cagney, Daniel , Grills, Inga S., Lee, Cheng-chia, Sheehan, Jason , Kluwe, Christien, Patel, Samir H. , Halasz, Lia M. , Andratschke, Nicolaus , Deibert, Christopher P., Cifarelli, Christopher P. , Debus, Jürgen, Aoyagi, Kyoko , Brown, Paul D. , Alami, Vida, Niranjan, Ajay , Lunsford, L. Dade , Camidge, D Ross, Kavanagh, Brian D. , Serizawa, Toru , Yamamoto, Masaaki, Bernhardt, Denise , Zacharia, Brad E , Andratschke, Nicolaus , Trifiletti, Daniel M , Mathieu, David , Robin, Tyler P. , Gao, Dexiang , Palmer, Joshua D. , Zacharia, Brad E. , Chan, Michael David , Braunstein, Steve , Verma, Vivek, Trifiletti, Daniel M. , Combs, Stephanie Elisabeth , Sato, Yasunori , Higuchi, Yoshinori , Kondziolka, Douglas

Mayo Clinic

JNCI: Journal of the National Cancer Institute | May 4, 2023 | Volume: 115 | Issue: 8 | Pages: 926-936

10.1093/jnci/djad073 | PMID 37142267 Get It

Abstract Introduction Historical reservations regarding stereotactic radiosurgery (SRS) for small-cell lung cancer (SCLC) brain metastases include concerns for short-interval and diffuse central nervous system (CNS) progression, poor prognoses, and increased neurological mortality specific to SCLC histology. We compared SRS outcomes for SCLC and non-small cell lung cancer (NSCLC) where SRS is well established. Methods Multicenter first-line SRS outcomes for SCLC and NSCLC from 2000 to 2022 were retrospectively collected (n = 892 SCLC, n = 4785 NSCLC). Data from the prospective Japanese Leksell Gamma Knife Society (JLGK0901) clinical trial of first-line SRS were analyzed as a comparison cohort (n = 98 SCLC, n = 814 NSCLC). Overall survival (OS) and CNS progression were analyzed using Cox proportional hazard and Fine-Gray models, respectively, with multivariable adjustment for cofactors including age, sex, performance status, year, extracranial disease status, and brain metastasis number and volume. Mutation-stratified analyses were performed in propensity score–matched retrospective cohorts of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) positive NSCLC, mutation-negative NSCLC, and SCLC. Results OS was superior for patients with NSCLC compared to SCLC in the retrospective dataset (median OS = 10.5 vs 8.6 months; P < .001) and in the JLGK0901 dataset. Hazard estimates for first CNS progression favoring NSCLC were similar in both datasets but reached statistical significance in the retrospective dataset only (multivariable hazard ratio = 0.82, 95% confidence interval = 0.73 to 0.92, P = .001). In the propensity score–matched cohorts, there were continued OS advantages for NSCLC patients (median OS = 23.7 [EGFR and ALK positive NSCLC] vs 13.6 [mutation-negative NSCLC] vs 10.4 months [SCLC], pairwise P values < 0.001), but no statistically significant differences in CNS progression were observed in the matched cohorts. Neurological mortality and number of lesions at CNS progression were similar for NSCLC and SCLC patients. Leptomeningeal progression was increased in patients with NSCLC compared to SCLC in the retrospective dataset only (multivariable hazard ratio = 1.61, 95% confidence interval = 1.14 to 2.26, P = .007). Conclusions After SRS, SCLC histology was associated with shorter OS compared to NSCLC. CNS progression occurred earlier in SCLC patients overall but was similar in patients matched on baseline factors. SCLC was not associated with increased neurological mortality, number of lesions at CNS progression, or leptomeningeal progression compared to NSCLC. These findings may better inform clinical expectations and individualized decision making regarding SRS for SCLC patients.
A Comparison of Clinical and Real-world Defined Pulmonary Arterial Hypertension (PAH) Cohorts in Electronic Health Records (EHR) From the Mayo Clinic
Carpenter, Corinne , Carlson, Katherine , Doddahonnaiah, Deeksha , Sasson, D., Silvert, Eli , Sandros, Marinella , Tobore, T., Wagner, Tyler E. , Bettencourt, K., DuBrock, Hilary M. , Tobore, T., Wagner, Tyler E , Bettencourt, K.

Mayo Clinic

D28. HOW CAN WE DO BETTER: EMERGING DIAGNOSTICS AND THERAPEUTICS IN PULMONARY VASCULAR DISEASE | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A6453-A6453

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6453 Get It

Characteristics of Bronchiectasis Patients Who Tested Positive for Coronavirus Disease 2019 - Data From the United States Bronchiectasis and Nontuberculous Mycobacterial Pulmonary Disease Research Registry
McShane, Pamela J. , Richards, C. , Sandi, M., Aksamit, T.R., Swenson, Colin , Metersky, Mark L. , Brunton, Amanda E. , Choate, Radmila

Mayo Clinic

B28. SOLVING THE PUZZLE OF BRONCHIECTASIS AND NONTUBERCULOUS MYCOBACTERIA | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A2956-A2956

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2956 Get It

Clinical Features of Patients With an Eosinophilic Phenotype: An Analysis of the U.S Bronchiectasis and NTM Research Registry
McShane, Pamela J. , Richards, C. , Aksamit, T.R., Restrepo, M.I., Maselli, Diego J , Brunton, Amanda E. , Choate, Radmila , Díaz, Alejandro A. , Swenson, Colin , Metersky, Mark L. , Tal‐Singer, Ruth , Restrepo, M.I.

Mayo Clinic

B103. HOT TOPICS IN CYSTIC FIBROSIS, BRONCHIECTASIS, AND BREATHLESSNESS | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A4310-A4310

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4310 Get It

Cftr Mutation and Increased Rates of Pulmonary Infections Among Patients From the US Bronchiectasis and NTM Research Registry
Richards, C. , Winthrop, K.L., McShane, Pamela J. , Knowles, M.R., Tino, Gregory , Aksamit, Timothy R. , Brunton, Amanda E. , Choate, Radmila , Maselli, Diego J , Swenson, Colin , Metersky, Mark L.

Mayo Clinic

B98. THE HAPPY COUPLE: BRONCHIECTASIS AND NONTUBERCULOUS MYCOBACTERIA | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A4244-A4244

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4244 Get It

Semantic Variant Primary Progressive Aphasia Associated with the C9orf72 Hexanucleotide Expansion – A Longitudinal Case Report (P13-6.004)
Switzer, Aaron , Fields, Julie A. , Kantarci, Kejal , Lowe, Val J. , Gavrilova, Ralitza H. , Forsberg, Leah K. , Nelson, Kevin L., Kolander, Tyler, Kantarci, Kejal , Switzer, Aaron R , Corriveau‐Lecavalier, Nick , Jones, David T. , Botha, Hugo , Knopman, David S. , Ramanan, Vijay K. , Lapid, Maria I. , Nelson, Kevin, Boeve, Bradley F.

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000203291 Get It

Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy
Bahr, Tyler , Bakri, Sophie J. , Bahr, Tyler A

Mayo Clinic

Life | April 28, 2023 | Volume: 13 | Issue: 5 | Pages: 1098

10.3390/life13051098 | PMID 37240743 Get It

Diabetic retinopathy (DR) is a microvascular disease caused by poorly controlled blood glucose, and it is a leading cause of vision loss in people with diabetes. In this review we discuss the current management of DR with particular focus on the use of intraocular anti-vascular endothelial growth factor (anti-VEGF) agents. Intraocular anti-VEGF agents were first studied in the 1990s, and now several of these agents are either FDA approved or used off-label as first-line treatments for DR. Recent evidence shows that anti-VEGF agents can halt the progression of markers of DR severity, reduce the risk of DR worsening, and reduce the onset of new macular edema. These significant benefits have been demonstrated in patients with proliferative DR and the milder nonproliferative DR (NPDR). A wealth of evidence from recent trials and meta-analyses has detailed the intraoperative and postoperative benefits of adjunctive anti-VEGF therapy prior to pars plana vitrectomy (PPV) for proliferative DR with vitreous hemorrhage. In this review, we also discuss literature comparing various anti-VEGF injection regimens including monthly, quarterly, as-needed, and treat and extend protocols. Combination protocols with panretinal photocoagulation (PRP) or PPV are also discussed. Current evidence suggests that anti-VEGF therapies are effective therapy for NPDR and PDR and may also provide significant benefits when used adjunctively with other DR treatment modalities such as PRP or PPV.